-
Uncategorized1 day ago
Sanofi stops immune drug trial in latest research setback
The failure adds to a series of mixed or negative readouts and leaves in doubt the future of a therapy Sanofi has viewed as a potential...
-
Uncategorized1 day agoGLP-1 reduces liver fat by 63%, trial results show
The glucagon/GLP-1 dual agonist survodutide could reduce liver fat by 63%, results show. Boehringer Ingelheim reported positive results from two Phase III trials, which demonstrated patients lost 63%...
-
Uncategorized1 day agoOB-GYN association, deviating from CDC guidance, issues its own vaccine recommendations
The American College of Obstetricians and Gynecologists has released a recommended vaccine schedule for pregnant people, one that diverges from the advice currently offered by the...
-
Uncategorized1 day ago
mRNA Tails Play Key Role in Folding Regulatory Proteins
mRNA 3′ UTRs have hundreds of highly conserved nucleotides, but their biological roles are unclear. In a new study published in Cell titled, “mRNA 3′ UTRs chaperone intrinsically...
-
Uncategorized1 day agoSTAT+: Pharmalittle: We’re reading about U.S. pressure on European drug prices, longer shortages, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember, there are only a few more days...
-
Uncategorized1 day ago
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy
The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug...
-
Uncategorized1 day ago
Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug
The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.
-
Uncategorized1 day agoThe State of Biologics Testing 2026
Read Now The success of modern biologics depends not only on groundbreaking science but on the robustness, speed, and credibility of the testing programs that support...
-
Uncategorized1 day ago
Update: Parabilis raises industry-record $670M IPO
Parabilis Medicines is joining the parade of biotechs going public, with one key difference—more money.
-
Uncategorized1 day agoDOJ reaches second settlement on youth gender care
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. Lately, I’ve been listening to the...
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
